Starting at: $680.00
| SKU | Package Size | Price | Quantity | Add to Cart |
|---|---|---|---|---|
| 10HU-238 | Cryopreserved, 0.5 million cells/vial | Starting at: $680.00 |
Product Description
Fibroblasts and myofibroblasts are believed to be the key effector cells in renal fibrogenesis responsible for the synthesis and deposition of extracellular matrix components [1]. Although fibroblasts are histologically visible in normal kidneys, there are relatively few of them and proximal tubular epithelial cells predominate. In progressive disease, however, the interstitium becomes filled with myofibroblasts [2]. Fibroblasts are considered the primary matrix-producing cells in the kidney and hence they are clinically relevant as principal mediators of renal fibrosis associated with progressive renal failure [3].
iXCells Biotechnologies provides high quality Human Renal Fibroblasts, which are isolated from adult human lung tissue and cryopreserved at P1, with >0.5 million cells in each vial. Human Renal Fibroblasts express fibronectin and are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast, and fungi. They can further expand no more than 3 passages in Fibroblast Growth Medium (Cat# MD-0011) under the condition suggested by iXCells Biotechnologies.
Figure 1. Human Renal Fibroblasts. (A) Phase contrast image. (B) Immunofluorescence staining with antibodies against Vimentin.
Product Details
| Tissue | Normal human kidney tissue |
| Package Size | 0.5 million cells/vial |
| Passage Number | P1 |
| Shipped | Cryopreserved |
| Storage | Liquid nitrogen |
| Growth Properties | Adherent |
| Media | Fibroblast Growth Medium (Cat# MD-0011) |
Reference
[1] Soma Meran and Robert Steadman (2011) “Fibroblasts and myofibroblasts in renal fibrosis”. Int. J. Exp. Path. 92: 158–167
[2] H. Terence Cook. (2010) “The Origin of Renal Fibroblasts and Progression of Kidney Disease”. The American Journal of Pathology, 176 (1):22-24.
[3] Frank Strutz and Michael Zeisberg. (2002) “Renal Fibroblasts and Myofibroblasts in Chronic Kidney Disease”. JASN, 17: 2992-2998.